Chai Discovery
Series CFrontier generative AI foundation models for programmable molecular and antibody drug design
Biotech AITotal Raised: $485M👥 51-200 Employees📍 San Francisco, USA
About Chai Discovery
Chai Discovery is developing frontier generative AI models to transform biology from an observational science into an engineering discipline. With models like Chai-3, the company designs de novo molecular compounds, therapeutic proteins, and antibodies from scratch in partnership with leading global biopharmaceutical leaders including Eli Lilly, Pfizer, and Novartis.
Founders & Leadership
Joshua MeierFounder & CEO
Jack DentCo-Founder
Investors & Backers
Funding History
3 roundsSeries CLATEST ROUNDValuation: $3.8B
Jul 14, 2026RAISED$400M
Open Careers at Chai Discovery
14 open rolesResearch•San Francisco office
Posted Sep 5, 2024Onsite
Outliers & Polymaths•San Francisco office
Posted Sep 5, 2024Onsite
Science•San Francisco office
Posted Feb 16, 2026Onsite
Partnerships•San Francisco office
Posted Mar 4, 2026Onsite
Platform & Products•San Francisco office
Posted Jun 30, 2025Onsite
Platform & Products•San Francisco office
Posted Jun 30, 2025Onsite